MA31308B1 - Anticorps antisclerostine. - Google Patents

Anticorps antisclerostine.

Info

Publication number
MA31308B1
MA31308B1 MA32274A MA32274A MA31308B1 MA 31308 B1 MA31308 B1 MA 31308B1 MA 32274 A MA32274 A MA 32274A MA 32274 A MA32274 A MA 32274A MA 31308 B1 MA31308 B1 MA 31308B1
Authority
MA
Morocco
Prior art keywords
antibodies
sclerostine
fight
bone
osteoporosis
Prior art date
Application number
MA32274A
Other languages
Arabic (ar)
English (en)
Inventor
Andrew Ihor Korytko
David Matthew Marquis
Eric Michael Smith
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31308B1 publication Critical patent/MA31308B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps humanisés et chimériques qui se lient spécifiquement à la sclérostine humaine et sont caractérisés en ce qu'ils présentent une affinité élevée et d'importantes propriétés de neutralisation. Les anticorps de l'invention sont utilisés pour augmenter la masse osseuse, la densité minérale osseuse et la résistance osseuse et pour traiter des troubles variés, par exemple, l'ostéoporose, chez un sujet humain.
MA32274A 2007-03-20 2009-10-12 Anticorps antisclerostine. MA31308B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20
PCT/US2008/056527 WO2008115732A2 (fr) 2007-03-20 2008-03-11 Anticorps antisclérostine

Publications (1)

Publication Number Publication Date
MA31308B1 true MA31308B1 (fr) 2010-04-01

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32274A MA31308B1 (fr) 2007-03-20 2009-10-12 Anticorps antisclerostine.

Country Status (31)

Country Link
US (3) US7744874B2 (fr)
EP (2) EP2664346A1 (fr)
JP (2) JP2010524846A (fr)
KR (1) KR101123487B1 (fr)
CN (1) CN101646457B (fr)
AU (1) AU2008229141B2 (fr)
BR (1) BRPI0809026A2 (fr)
CA (1) CA2682212C (fr)
CO (1) CO6230999A2 (fr)
CR (1) CR11004A (fr)
CY (1) CY1114784T1 (fr)
DK (1) DK2131860T3 (fr)
DO (1) DOP2009000223A (fr)
EA (1) EA018204B1 (fr)
EC (1) ECSP099658A (fr)
ES (1) ES2446293T3 (fr)
HR (1) HRP20140108T1 (fr)
IL (1) IL200437A0 (fr)
MA (1) MA31308B1 (fr)
MX (1) MX2009010051A (fr)
MY (1) MY149129A (fr)
NZ (1) NZ578870A (fr)
PL (1) PL2131860T3 (fr)
PT (1) PT2131860E (fr)
RS (1) RS53157B (fr)
SI (1) SI2131860T1 (fr)
SV (1) SV2009003374A (fr)
TN (1) TN2009000383A1 (fr)
UA (1) UA96474C2 (fr)
WO (1) WO2008115732A2 (fr)
ZA (1) ZA200906345B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CA2529623A1 (fr) 2003-06-16 2005-02-17 Celltech R & D, Inc. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP3345607B1 (fr) 2006-12-29 2022-10-26 Ossifi-Mab LLC Procédés de modification de croissance osseuse par administration d'antagoniste ou d'agoniste sost ou wise
MY149129A (en) * 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
EP2558106A1 (fr) 2010-04-16 2013-02-20 Novartis AG Procédés et compositions pour améliorer l'ostéointégration d'implant
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
NZ605260A (en) * 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
EP2647706B1 (fr) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
EP3604339B1 (fr) 2011-01-14 2021-03-10 The Regents Of The University Of California Anticorps thérapeutiques contre la protéine ror-1 et leurs procédés d'utilisation
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
AP3981A (en) 2011-03-25 2017-01-05 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
US20140127192A1 (en) 2011-04-19 2014-05-08 Amgen Inc Method for treating osteoporosis
WO2012149246A1 (fr) 2011-04-29 2012-11-01 Novartis Ag Méthodes de traitement du carcinome épidermoïde et applications associées
SI2739311T1 (en) * 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
HK1200322A1 (en) * 2011-10-24 2015-08-07 Abbvie Inc. Immunobinders directed against sclerostin
RU2014121043A (ru) 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
PE20141545A1 (es) 2011-10-24 2014-11-26 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
EP3712168A3 (fr) * 2011-12-28 2020-10-14 Amgen Inc. Procédé de traitement d'une perte osseuse alvéolaire au moyen d'anticorps anti-sclérostine
AU2013285488B2 (en) * 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
WO2014015133A1 (fr) 2012-07-19 2014-01-23 National Cheng Kung University Traitement de l'ostéoarthrite au moyen d'antagonistes d'il-20
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (fr) 2013-01-31 2014-08-07 Novartis Ag Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2014155278A2 (fr) 2013-03-26 2014-10-02 Novartis Ag Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MX391051B (es) 2014-12-30 2025-03-21 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
SI3269735T1 (sl) * 2015-03-13 2020-12-31 Jiangsu Hengrui Medicine Co. Ltd. Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
CA3015619A1 (fr) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticorps specifiques du recepteur du poliovirus humain (pvr)
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
KR20190037261A (ko) 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
CA3038850A1 (fr) * 2016-10-28 2018-05-03 Eli Lilly And Company Anticorps anti-rankl et leurs utilisations
JP2019533458A (ja) * 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
WO2018139623A1 (fr) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-sclérostine et procédés d'utilisation
WO2018227187A1 (fr) * 2017-06-09 2018-12-13 The Regents Of The University Of California Pro-gélateurs peptidiques cycliques injectables par cathéter pour l'ingénierie tissulaire myocardique
CN109952093B (zh) * 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
EP3774879B1 (fr) 2018-03-30 2026-01-28 Amgen Inc. Variants d'anticorps anti-c-terminal
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
MA53272A (fr) 2018-08-10 2021-11-17 Amgen Inc Procédé de préparation d'une formulation pharmaceutique d'anticorps
US12122843B2 (en) 2019-01-22 2024-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
EP4013786A1 (fr) 2019-08-12 2022-06-22 Amgen Inc. Formulations d'anticorps anti-sclérostine
EP4041392A1 (fr) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Anticorps dirigés contre le récepteur du poliovirus (pvr) et leurs utilisations
AR133302A1 (es) 2023-07-19 2025-09-17 Amgen Inc Métodos de preparación de amortiguador para una formulación de proteína terapéutica
WO2025081137A1 (fr) * 2023-10-12 2025-04-17 The Regents Of The University Of Michigan Agents thérapeutiques ciblant les os
CN119097708B (zh) * 2024-09-04 2025-05-09 中国医学科学院北京协和医院 Dkk1单克隆抗体在制备用于治疗骨质疏松症的药物组合物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481487T1 (de) * 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1366156A2 (fr) 2000-06-19 2003-12-03 F. Hoffmann-La Roche Ag Polymorphismes genetiques d'osteolevine
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2003283206A1 (en) * 2002-11-27 2004-06-18 Aventis Pharma Deutschland Gmbh A method and a system for establishing a quantity measure for joint destruction
CA2529623A1 (fr) * 2003-06-16 2005-02-17 Celltech R & D, Inc. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
WO2005005604A2 (fr) 2003-06-30 2005-01-20 Centocor, Inc. Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
AU2004324464A1 (en) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc. Methods of optimizing antibody variable region binding affinity
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP2423226A3 (fr) 2006-11-10 2012-05-30 Amgen Inc. Diagnostic à base d'anticorps et thérapeutique
MY149129A (en) * 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies

Also Published As

Publication number Publication date
CA2682212C (fr) 2014-05-06
US20090060924A1 (en) 2009-03-05
RS53157B (sr) 2014-06-30
BRPI0809026A2 (pt) 2014-09-23
MX2009010051A (es) 2009-10-12
JP5758933B2 (ja) 2015-08-05
PT2131860E (pt) 2014-03-04
WO2008115732A2 (fr) 2008-09-25
US7744874B2 (en) 2010-06-29
SI2131860T1 (sl) 2014-02-28
CA2682212A1 (fr) 2008-09-25
ZA200906345B (en) 2010-11-24
US20100221263A1 (en) 2010-09-02
CN101646457B (zh) 2013-05-01
EA018204B1 (ru) 2013-06-28
KR20090114462A (ko) 2009-11-03
JP2010524846A (ja) 2010-07-22
ECSP099658A (es) 2009-10-30
US8257704B2 (en) 2012-09-04
MY149129A (en) 2013-07-15
SV2009003374A (es) 2011-01-10
EP2131860A2 (fr) 2009-12-16
DOP2009000223A (es) 2009-10-15
HK1138790A1 (en) 2010-09-03
AU2008229141B2 (en) 2013-02-07
IL200437A0 (en) 2010-04-29
EA200970874A1 (ru) 2010-02-26
CR11004A (es) 2009-11-02
CO6230999A2 (es) 2010-12-20
JP2013151504A (ja) 2013-08-08
PL2131860T3 (pl) 2014-05-30
EP2131860B1 (fr) 2013-12-18
NZ578870A (en) 2012-01-12
US20110250205A1 (en) 2011-10-13
HRP20140108T1 (hr) 2014-02-28
US7988970B2 (en) 2011-08-02
KR101123487B1 (ko) 2012-03-23
CN101646457A (zh) 2010-02-10
TN2009000383A1 (en) 2010-12-31
EP2664346A1 (fr) 2013-11-20
DK2131860T3 (da) 2014-01-13
AU2008229141A1 (en) 2008-09-25
CY1114784T1 (el) 2016-12-14
UA96474C2 (en) 2011-11-10
WO2008115732A3 (fr) 2008-12-11
ES2446293T3 (es) 2014-03-07

Similar Documents

Publication Publication Date Title
MA31308B1 (fr) Anticorps antisclerostine.
NL301196I1 (fr)
SG153878A1 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TW200736274A (en) Immunoglobulins
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
TNSN04078A1 (fr) Antibodies to cd40
MY149630A (en) Antibodies against amyloid-beta peptide
GEP20104922B (en) Antibodies to m-csf
UA117807C2 (uk) ІМУНОКОН'ЮГАТ, ЩО МІСТИТЬ РЕКОМБІНАНТНЕ АНТИТІЛО ДО РЕЦЕПТОРА ЕПІДЕРМАЛЬНОГО ФАКТОРА РОСТУ ЛЮДИНИ (hEGFR), ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА ЙОГО МІСТИТЬ
WO2006125640A3 (fr) Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
UA95478C2 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТ с-Kit
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
MX2009006891A (es) Anticuerpos cd44.
WO2007042309A3 (fr) Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
MX346172B (es) Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
EA201300418A1 (ru) Антитела к человеческому tweak и варианты их применения
EP3345925A3 (fr) Anticorps humanisés ciblant le domaine ec1 cadhérine-11 et compositions et procédés associés
MA38161A1 (fr) Anticorps anti-bmp-6
SI2791177T1 (en) Molecules that bind thrombin antibodies and their use
WO2009000929A3 (fr) Composition et procédé de traitement de maladie auto-immune
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo